Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1040 SPRING ST SILVER SPRING MD 20910 USA

P: 301-608-9292 F: 301-608-9291

Description:

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

Key Statistics

Overview:

Market Capitalization, $K 8,988,194
Shares Outstanding, K 44,923
Annual Sales, $ 1,483 M
Annual Net Income, $ 514,800 K
Last Quarter Sales, $ 446,500 K
Last Quarter Net Income, $ 172,600 K
60-Month Beta 0.49
% of Insider Shareholders 12.10%
% of Institutional Shareholders 94.95%
Float, K 39,487
% Float 87.90%

Growth:

1-Year Return 87.57%
3-Year Return 63.01%
5-Year Return 57.28%
5-Year Revenue Growth 1.20%
5-Year Earnings Growth -9.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 4.09 on 08/04/21
Next Earnings Date 10/27/21
Earnings Per Share ttm 10.29
EPS Growth vs. Prev Qtr 498.36%
EPS Growth vs. Prev Year 51.45%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 19.94
Price/Earnings forward 8.72
Price/Earnings to Growth N/A
Return-on-Equity % 13.69%
Return-on-Assets % 10.18%
Profit Margin % 34.71
Net Margin % 20.32
Debt/Equity 0.23
Price/Sales 6.21
Price/Cash Flow 16.59
Price/Book 2.60
Book Value/Share 81.08
Interest Coverage 28.19
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar